A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors
Status: | Recruiting |
---|---|
Conditions: | Cancer, Blood Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 10/31/2018 |
Start Date: | January 2016 |
End Date: | June 2020 |
Contact: | Anca Milea, MSc, PMP |
Email: | anca@trilliumtherapeutics.com |
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory
hematologic malignancies and selected solid tumors.
hematologic malignancies and selected solid tumors.
This is a trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies
and selected solid tumors.
TTI-621 (SIRPαFc) is a soluble recombinant fusion protein created by directly linking the
sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of
human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from
delivering an inhibitory "do not eat" (anti phagocytic) signal to macrophages.
This trial will be conducted in 2 phases: Phase 1a (escalation phase) and Phase 1b (expansion
phase).
In the dose Escalation Phase (phase 1a), subjects with lymphoma will be enrolled in
sequential dose cohorts to receive TTI-621 to characterize safety, tolerability,
pharmacokinetics, and the maximum-tolerated dose (MTD).
In the Expansion Phase (phase 1b), TTI-621 will be given to subjects with a variety of
hematologic malignancies and selected solid tumors to further define safety and to
characterize efficacy. In the Expansion Phase, the safety and efficacy of TTI-621 will also
be assessed when it is given in combination with other anti-cancer drugs. The dose of TTI-621
to be delivered in the Expansion Phase of the study may be increased or decreased based on
the subject's tolerability and on the subject's response to treatment.
Secondary objectives include further characterization of the pharmacokinetics,
pharmacodynamics, and development of ADA; and to gain preliminary evidence of the anti-tumor
activity of TTI-621 in subjects with a variety of hematologic malignancies and selected solid
tumors.
and selected solid tumors.
TTI-621 (SIRPαFc) is a soluble recombinant fusion protein created by directly linking the
sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of
human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from
delivering an inhibitory "do not eat" (anti phagocytic) signal to macrophages.
This trial will be conducted in 2 phases: Phase 1a (escalation phase) and Phase 1b (expansion
phase).
In the dose Escalation Phase (phase 1a), subjects with lymphoma will be enrolled in
sequential dose cohorts to receive TTI-621 to characterize safety, tolerability,
pharmacokinetics, and the maximum-tolerated dose (MTD).
In the Expansion Phase (phase 1b), TTI-621 will be given to subjects with a variety of
hematologic malignancies and selected solid tumors to further define safety and to
characterize efficacy. In the Expansion Phase, the safety and efficacy of TTI-621 will also
be assessed when it is given in combination with other anti-cancer drugs. The dose of TTI-621
to be delivered in the Expansion Phase of the study may be increased or decreased based on
the subject's tolerability and on the subject's response to treatment.
Secondary objectives include further characterization of the pharmacokinetics,
pharmacodynamics, and development of ADA; and to gain preliminary evidence of the anti-tumor
activity of TTI-621 in subjects with a variety of hematologic malignancies and selected solid
tumors.
Inclusion Criteria:
1. Advanced measurable malignancy
2. Adequate hematologic status
3. Relapsed or are refractory following at least 2 prior systemic therapeutic attempts (1
prior systemic attempt for PTCL). For CTCL, extracorporal photochemotherapy (ECP) will
be considered a systemic therapy. Local radiation and topical agents are not systemic
therapies.
4. Adequate coagulation function
5. Adequate hepatic function
6. Adequate renal function
Exclusion Criteria:
1. Known, current central nervous system disease involvement or untreated brain
metastases
2. Allogeneic transplant within 30 days prior to the planned start of treatment or
subjects with active graft-vs-host disease with the exception of Grade 1 skin
involvement
3. History of hemolytic anemia or bleeding diathesis
We found this trial at
15
sites
1721 East 19th Ave., Suite #200 & #300
Denver, Colorado 80218
Denver, Colorado 80218
720-754-4800
Phone: 877-691-7274
Colorado Blood Cancer Institute When patients come to the Colorado Blood Cancer Institute, the entire...
Click here to add this to my saved trials
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
Duarte, California 91010
626-256-HOPE (4673)
Phone: 626-256-4673
City of Hope National Medical Center City of Hope is dedicated to making a difference...
Click here to add this to my saved trials
Hackensack, New Jersey 07601
Phone: 551-996-5168
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
Nashville, Tennessee 37023
615-320-5090
Phone: 877-691-7274
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
Click here to add this to my saved trials
Click here to add this to my saved trials
160 East 34th Street
New York, New York 10016
New York, New York 10016
Phone: 646-501-7869
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Phone: 646-888-4593
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
Pittsburgh, Pennsylvania 15213
Phone: 412-864-3681
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials